Bioerg Spólka Akcyjna (WSE:BER) - Share price, News & Analysis

BER fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

BER Stock Overview

Bioerg Spólka Akcyjna focuses on trading of food and chemical products in Poland.

Risk Analysis

Earnings have declined by 82.6% per year over past 5 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Does not have a meaningful market cap (PLN17M)

+ 2 more risks

Bioerg Spólka Akcyjna Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bioerg Spólka Akcyjna
Historical stock prices
Current Share Price	zł0.17
52 Week High	zł0.31
52 Week Low	zł0.10
Beta	0.76
1 Month Change	-6.61%
3 Month Change	19.37%
1 Year Change	-41.55%
3 Year Change	69.50%
5 Year Change	54.09%
Change since IPO	-75.79%

Shareholder Returns

	BER	PL Biotechs	PL Market
7D	-1.2%	-0.2%	1.5%
1Y	-41.6%	-38.3%	-14.0%

Return vs Industry: BER underperformed the Polish Biotechs industry which returned -40% over the past year.

Return vs Market: BER underperformed the Polish Market which returned -15.6% over the past year.

Price Volatility

Is BER's price volatile compared to industry and market?
BER volatility
BER Average Weekly Movement	17.7%
Biotechs Industry Average Movement	7.3%
Market Average Movement	6.9%
10% most volatile stocks in PL Market	13.4%
10% least volatile stocks in PL Market	4.5%

Stable Share Price: BER is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: BER's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

Founded	Employees	CEO	Website
2007	1	Piotr Klomfas	https://www.bioerg.pl

Bioerg Spólka Akcyjna focuses on trading of food and chemical products in Poland. It engages in the wholesale and retail trade of ecological food products for humans and animals; and household chemical products. The company also undertakes technical maintenance of industrial installations; repairs installations, equipment, and industrial fittings; repairs and services machines; implements tasks related to prefabrication; and provides technical consultancy, cleaning, and machining services.

Bioerg Spólka Akcyjna Fundamentals Summary

How do Bioerg Spólka Akcyjna's earnings and revenue compare to its market cap?
BER fundamental statistics
Market Cap	zł17.24m
Earnings (TTM)	-zł12.71m
Revenue (TTM)	zł5.08m

3.4x

P/S Ratio

-1.4x

P/E Ratio

Is BER overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BER income statement (TTM)
Revenue	zł5.08m
Cost of Revenue	zł1.08m
Gross Profit	zł3.99m
Other Expenses	zł16.70m
Earnings	-zł12.71m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Aug 10, 2022

Earnings per share (EPS)	-0.12
Gross Margin	78.65%
Net Profit Margin	-250.37%
Debt/Equity Ratio	79.9%

How did BER perform over the long term?

See historical performance and comparison

Valuation

Is Bioerg Spólka Akcyjna undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

38.26x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BER's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BER's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: BER is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.

PE vs Market: BER is unprofitable, so we can't compare its PE Ratio to the Polish market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BER's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BER is overvalued based on its PB Ratio (38.3x) compared to the PL Biotechs industry average (4.5x).

Future Growth

How is Bioerg Spólka Akcyjna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

42.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioerg Spólka Akcyjna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Bioerg Spólka Akcyjna performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-82.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BER is currently unprofitable.

Growing Profit Margin: BER is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: BER is unprofitable, and losses have increased over the past 5 years at a rate of 82.6% per year.

Accelerating Growth: Unable to compare BER's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BER is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: BER has a negative Return on Equity (-2819.17%), as it is currently unprofitable.

Financial Health

How is Bioerg Spólka Akcyjna's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BER's short term assets (PLN1.1M) exceed its short term liabilities (PLN962.5K).

Long Term Liabilities: BER's short term assets (PLN1.1M) exceed its long term liabilities (PLN2.5K).

Debt to Equity History and Analysis

Debt Level: BER has more cash than its total debt.

Reducing Debt: BER's debt to equity ratio has increased from 0.02% to 79.9% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BER has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BER has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33% each year

Dividend

What is Bioerg Spólka Akcyjna current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BER's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BER's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BER's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BER's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BER has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average board tenure

CEO

Piotr Klomfas

1.67yrs

Tenure

Mr. Piotr Klomfas serves as Chairman of Management Board at Bioerg Spólka Akcyjna since September 2020.

Board Members

Experienced Board: BER's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/09/30
Annual Earnings	2020/12/31